Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market

03-Apr-2007

Alnylam Pharmaceuticals, Inc. announced today that it has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.

"Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG. "This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property."

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination - Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics

Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

4SC strengthens patent protection for its epigenetic cancer drug in China

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

Heptares enters a research and drug discovery collaboration with Juntendo University

Novasep and instrAction enter a worldwide strategic alliance for non-chiral chromatography

Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents